August 2012
-
According to Meda Pharmaceuticals, a Phase 3 trial has shown that its Dymista nasal spray, a combination formulation of azelastine hydrochloride and fluticasone propionate, produced a 40% greater improvement in nasal symptoms than fluticasone alone.… Read more . . .
-
Vectura’s VR496, an inhaled dry powder formulation of heparin sodium, has produced positive results in a Phase 2 study in cystic fibrosis patients, says the company. The product has received orphan drug status from both… Read more . . .
-
Results from the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) study published in the New England Journal of Medicine show a significant reduction in exacerbations for COPD patients treated with tiotropium compared to those… Read more . . .
-
The FDA has informed Novartis that it needs a three-month extension for its review of data supporting the company’s NDA for QAB149 (indacaterol). The new completion date for the review would be July 2011. The… Read more . . .
-
According to Verona Pharma, the company spent nearly £1 million in 2010 on development of its lead product, RPL554, an inhaled PDE3/4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis. Those R&D costs… Read more . . .
-
The US Supreme Court ruled unanimously that Matrixx Initiatives was wrong when it claimed that it did not have to disclose reports of adverse effects caused by its Zicam nasal spray because the number of… Read more . . .
-
Send workshop and paper proposals by Friday, 29th April 2011. The main theme for the 2012 conference will be sustainability Possible paper and workshop themes may be: new areas of application, materials, surface treatment, shaping,… Read more . . .
-
According to Virginia biotech company Insmed, the US FDA has cleared the company’s Investigational New Drug (IND) application for a Phase 3 trial of its Arikace liposomal amikacin for inhalation in nontuberculous mycobacteria lung infections.… Read more . . .
-
According to reports, Novartis will close its manufacturing facility at Horsham, UK, cutting 550 jobs, but will maintain its respiratory research program at the site. The company employs approximately 330 researchers in the respiratory program.… Read more . . .
-
The Allergy and Asthma Network Mothers of Asthmatics (AANMA) has published results of a new survey of US asthma patients. Of the patients surveyed, 100% reported use of a short-acting bronchodilator, and 95% reported that… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland